Takeda’s Velcade Reaches $1 Billion Blockbuster Status
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical's Velcade (bortezomib) for treating multiple myeloma officially reached blockbuster status in November, hitting the $1 billion mark in sales. The drug, co-marketed by its Millennium Pharmaceutical subsidiary and U.S.-based Johnson & Johnson, added sales in part by gaining an additional indication from U.S. FDA beyond it previous limit to patients who failed to respond to other drugs. The huge sales were realized despite the drug's $40,000 average price tag for a nine-month treatment. (Click here for more - a subscription may be required